Citations

A novel ultrasound technique was used to assess the superior segment of the internal jugular vein (IJV) in healthy individuals, evaluating the feasibility of visualizing this vein through the parotid gland and examining positional changes. Eighty-five patients undergoing unrelated carotid ultrasound were included, excluding those with headaches, migraines, or other neurological symptoms. A transducer was placed over the parotid gland, and gray scale images—with and without diameter measurement—and color and spectral Doppler of the IJV were obtained in neutral and head turned contralaterally. Technical feasibility and quantitative measurements with mean values and standard deviations were reported. Significant positional changes were assessed if paired data were available. Successful diameter measurements were obtained in at least one side in 79% to 80% of patients and bilaterally in 75%. Mean diameters were 5.5 cm (right) and 5 cm (left). Velocities were acquired in 82% (unilaterally) and 78% (bilaterally). Mean peak systolic velocities were 42 cm/s (right) and 32 cm/s (left). With head rotation, mean velocities were 46 cm/s (right) and 38 cm/s (left). In patients with paired measurements, velocities increased by over 50% in 19% to 28% of patients ( P <0.05 for both sides). There was no significant change in the diameter when the head was turned. Visualization of the superior IJV using a parotid window and evaluation of its diameter and internal velocities are feasible with the head in both neutral position and turned contralaterally.

INTRODUCTION: Chronic gastrointestinal (GI) conditions, including irritable bowel syndrome and other disorders of gut-brain interaction, are prevalent and costly, and fragmented care contributes to suboptimal outcomes. Virtual and multidisciplinary care models may improve outcomes. Objectives: We aimed to (i) characterize patients receiving virtual GI care, (ii) report patient engagement with and patient-reported outcomes after virtual multidisciplinary care, and (iii) report healthcare utilization and costs from a payer perspective among patients vs propensity score-matched controls identified from claims data. METHODS: We collected descriptive data on patient demographics, clinic provider visits, symptoms, and patient-reported outcomes from 3/2021 to 9/2022. To evaluate healthcare utilization and costs, we conducted difference-in-difference analyses using claims data compared with a propensity score-matched control group. RESULTS: Among 234 patients (71% women, mean age 45.4 ± 13.2 years), 51% received a new GI diagnosis, predominately disorders of gut-brain interaction (63%). Engagement criteria were met by 80% (n = 187), who completed a mean of 10 visits and median time-to-first appointment of 6 days. Dietitians (93%), psychologists (76%), and health coaches (64%) were frequently used. Engaged patients exhibited significant improvements from preclinic to postclinic in irritable bowel syndrome severity (226.7–145.6), symptom control (20.2%–86.6%), quality-of-life dysphoria (27.5–32.8), missed workdays (1.0–0.7), and satisfaction (37.4%–96.3%) (all P < 0.05). Compared with matched controls, a significantly smaller percent of patients had imaging (15% vs 44%; P < 0.0001) and GI-related emergency department visits (4% vs 10%; P = 0.0028), which contributed to reductions in GI-related costs ($443 per member per month; P = 0.047) and all-cause costs ($676 per member per month; P = 0.043), equating to annualized savings of $5,316 and $8,112, respectively. DISCUSSION: Virtual multidisciplinary GI care was associated with high engagement, improved clinical outcomes, and reduced healthcare utilization and costs.

Abstract Vertebral metastatic disease results from many types of cancer and can have a devastating impact on patient mobility, psychological health, quality of life, and ultimately overall patient survival. However, the development of radiotherapy and surgical techniques has rapidly surged in conjunction with ongoing advances in basic science and translational studies. In this review, we discuss the paradigm shift in our understanding of the epidemiology and treatment algorithms for spinal oncology, ranging from preoperative optimization strategies, radiation and surgical techniques, the utilization of molecular markers and targeted therapeutics in medical oncology, and prognostication tools that underscore a new multidisciplinary approach to spinal oncology care.

Abstract Neurosurgical oncology is a rapidly advancing field, driven by interdisciplinary collaboration, technological innovation, and a growing understanding of tumor biology. As we celebrate the 40th anniversary of the AANS/CNS Section on Tumors, this editorial highlights the collaborative spirit that defines the Section and explores the many ways it intersects with other neurosurgical subspecialties and AANS/CNS Sections to optimize patient care. This special edition features a series of articles showcasing these intersections across functional, cerebrovascular, spine, trauma, pain, and pediatric neurosurgery. For example, insights into neuron–glioma interactions—enhanced by tools such as optogenetics and advanced brain mapping—are opening doors to more personalized treatment strategies. Innovations in preoperative embolization for skull base meningiomas are improving surgical precision and outcomes. Similarly, advances in managing vertebral metastatic disease with surgical techniques and stereotactic body radiation therapy (SBRT) are reshaping standards of care. Neuro-intensive care has evolved to support personalized postoperative recovery, with a focus on neurological function and cognitive rehabilitation. In pain management, neuromodulation, including intrathecal drug delivery and spinal cord stimulation, is offering new relief to tumor patients. Adolescents and young adults (AYA) with gliomas remain an underserved population, requiring age-specific treatment frameworks and better integration into clinical trials. This edition celebrates the diverse and collaborative workforce propelling neurosurgical oncology forward.

ABSTRACT Evaluating patients following a COVID‐19 infection with multiple chronic, progressive symptoms can be challenging, but easy to navigate by using the temporal profile obtained from the clinical history, findings from the neurological exam, and screening for red flag symptoms.

Objective To validate International Bladder Cancer Group (IBCG) definitions of Bacillus Calmette‐Guérin (BCG)‐unresponsive and BCG‐exposed non‐muscle‐invasive bladder cancer (NMIBC) and assess prognostic heterogeneity across various BCG‐failure types. Patients and Methods From a multicentre international cohort of 3806 BCG‐treated patients, 591 who developed high‐grade NMIBC recurrence following BCG between 2003 and 2024 were included. Progression‐free survival (PFS) was the primary endpoint; cancer‐specific (CSM) and overall mortality (OM) were secondary endpoints. Cumulative incidence functions, competing‐risk models and multivariable Cox regression were used. Results Patients with BCG‐unresponsive and BCG‐exposed disease showed similar PFS, CSM, and OM (all P > 0.05). When stratified into five subgroups, prognosis varied: 5‐year progression rates were 29% for BCG‐unresponsive, 32.5% for late relapse (between 6 and 24 months) after adequate BCG, 30% for BCG‐exposed with inadequate BCG (<24 months from induction), 6.2% for BCG‐resistant, and 14% for very late relapse (>24 months since last BCG) ( P < 0.01). In multivariable analysis, BCG‐exposed after inadequate BCG (subdistribution hazard ratio [sHR] 3.42, 95% confidence interval [CI] 1.33–8.84), late relapse (sHR 3.74, 95% CI 1.59–8.78), and BCG‐unresponsive (sHR 2.34, 95% CI 1.00–5.44) were associated with higher progression risks compared to very late relapse. Limitations include retrospective design and treatment heterogeneity. Conclusions Under IBCG definitions, BCG‐unresponsive and BCG‐exposed NMIBC have similarly poor outcomes. A refined classification reveals prognostic heterogeneity, with late relapses after adequate BCG demonstrating outcomes comparable to BCG‐unresponsive, and very late relapses conferring better prognosis.

Background Medication nonadherence has been associated with poor outcomes in transplant recipients yet identifying these behaviors pre-transplant remains challenging. The simplified medication adherence questionnaire (SMAQ) is a brief, reliable instrument to assess medication adherence. The aim of this study was to perform SMAQ testing on thoracic organ candidates and examine correlations between these scores and individual patient factors predicting medication nonadherence. Methods Consenting waitlisted lung, heart, and heart-lung transplant candidates from six thoracic transplant centers were mailed a survey that included demographic information and the Simplified Medication Adherence Questionnaire (SMAQ). Univariate logistic regression analysis was performed to assess association between pre-transplant medication adherence and demographic characteristics, psychosocial factors, and mortality. Results Among 298 participants, 60.7% were medication nonadherent. Nonadherence was associated with some college education (OR: 1.73; CI: 1.06, 2.81), lower positive affect (OR: 0.95; CI: 0.92, 0.99), and higher uncertainty (OR: 1.02; CI: 1.01, 1.04). Higher positivity ratio predicted adherence. Conclusion Identifiable patient-specific characteristics associated with medication nonadherence can be screened for during thoracic transplant evaluation. Interventions aimed at improving these factors during the pre-transplant period may improve clinical post-transplant outcomes, however, larger studies are needed to validate these findings.